Cargando…

Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma

Definitive chemoradiotherapy (dCRT) for the esophageal squamous cell carcinoma (ESCC) is performed for patients with cT4 disease without distant metastasis and also for those with cStage I‐III who are unable to tolerate or who refuse surgery. The rates of clinical complete response (cCR) after dCRT...

Descripción completa

Detalles Bibliográficos
Autores principales: Yagi, Koichi, Toriumi, Tetsuro, Aikou, Susumu, Yamashita, Hiroharu, Seto, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316734/
https://www.ncbi.nlm.nih.gov/pubmed/34337292
http://dx.doi.org/10.1002/ags3.12448
_version_ 1783729924281991168
author Yagi, Koichi
Toriumi, Tetsuro
Aikou, Susumu
Yamashita, Hiroharu
Seto, Yasuyuki
author_facet Yagi, Koichi
Toriumi, Tetsuro
Aikou, Susumu
Yamashita, Hiroharu
Seto, Yasuyuki
author_sort Yagi, Koichi
collection PubMed
description Definitive chemoradiotherapy (dCRT) for the esophageal squamous cell carcinoma (ESCC) is performed for patients with cT4 disease without distant metastasis and also for those with cStage I‐III who are unable to tolerate or who refuse surgery. The rates of clinical complete response (cCR) after dCRT differ depending on the cStage, and patients who once achieved cCR frequently experience tumor recurrence. For those with residual tumor or with recurrence, salvage treatment is performed to achieve a cure. Several procedures have been reported as salvage treatments. Salvage esophagectomy is associated with high rates of morbidity and mortality, but can offer long‐term survival. With R0 resection, with cCR to dCRT, pulmonary complications appear to be important prognostic factors affecting overall survival (OS). Lymphadenectomy is performed for the patients with lymph node metastasis without recurrence of primary lesions or distant metastasis, but the contribution to long‐term OS is unclear. Metastasectomy is performed when distant metastasis is limited to the lung and there are few lesions, possibly contributing to long‐term OS. Endoscopic resection and photodynamic therapy are indicated for cT1a and cT1‐2 residual or recurrent tumors, respectively, and can yield favorable outcomes. Re‐CRT and re‐radiotherapy are performed for the patients with contraindications for surgery, but neither appears to contribute to long‐term OS despite high incidences of esophageal fistula and perforation.
format Online
Article
Text
id pubmed-8316734
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83167342021-07-31 Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma Yagi, Koichi Toriumi, Tetsuro Aikou, Susumu Yamashita, Hiroharu Seto, Yasuyuki Ann Gastroenterol Surg Review Articles Definitive chemoradiotherapy (dCRT) for the esophageal squamous cell carcinoma (ESCC) is performed for patients with cT4 disease without distant metastasis and also for those with cStage I‐III who are unable to tolerate or who refuse surgery. The rates of clinical complete response (cCR) after dCRT differ depending on the cStage, and patients who once achieved cCR frequently experience tumor recurrence. For those with residual tumor or with recurrence, salvage treatment is performed to achieve a cure. Several procedures have been reported as salvage treatments. Salvage esophagectomy is associated with high rates of morbidity and mortality, but can offer long‐term survival. With R0 resection, with cCR to dCRT, pulmonary complications appear to be important prognostic factors affecting overall survival (OS). Lymphadenectomy is performed for the patients with lymph node metastasis without recurrence of primary lesions or distant metastasis, but the contribution to long‐term OS is unclear. Metastasectomy is performed when distant metastasis is limited to the lung and there are few lesions, possibly contributing to long‐term OS. Endoscopic resection and photodynamic therapy are indicated for cT1a and cT1‐2 residual or recurrent tumors, respectively, and can yield favorable outcomes. Re‐CRT and re‐radiotherapy are performed for the patients with contraindications for surgery, but neither appears to contribute to long‐term OS despite high incidences of esophageal fistula and perforation. John Wiley and Sons Inc. 2021-03-10 /pmc/articles/PMC8316734/ /pubmed/34337292 http://dx.doi.org/10.1002/ags3.12448 Text en © 2021 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Yagi, Koichi
Toriumi, Tetsuro
Aikou, Susumu
Yamashita, Hiroharu
Seto, Yasuyuki
Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma
title Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma
title_full Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma
title_fullStr Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma
title_full_unstemmed Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma
title_short Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma
title_sort salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316734/
https://www.ncbi.nlm.nih.gov/pubmed/34337292
http://dx.doi.org/10.1002/ags3.12448
work_keys_str_mv AT yagikoichi salvagetreatmentafterdefinitivechemoradiotherapyforesophagealsquamouscellcarcinoma
AT toriumitetsuro salvagetreatmentafterdefinitivechemoradiotherapyforesophagealsquamouscellcarcinoma
AT aikoususumu salvagetreatmentafterdefinitivechemoradiotherapyforesophagealsquamouscellcarcinoma
AT yamashitahiroharu salvagetreatmentafterdefinitivechemoradiotherapyforesophagealsquamouscellcarcinoma
AT setoyasuyuki salvagetreatmentafterdefinitivechemoradiotherapyforesophagealsquamouscellcarcinoma